Aurinia Pharmaceuticals Reports Strong Profit Growth Amid New Competition for Its Key Drug
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported a significant increase in profits during the second quarter of 2026, driven by strong revenue growth from its flagship drug LUPKYNIS. Revenue rose 19% to $83.2 million for the quarter, with net income surging 74% to $37.4 million. The lupus nephritis treatment accounted for nearly all of this success, generating $79.4 million in sales during the period. Despite these gains, there are underlying concerns as R&D spending doubled and tax expenses increased sharply due to rising pretax income. Aurinia also reported an accumulated deficit of $577.6 million at June 30, reflecting ongoing financial pressures from its earlier years before profitability was achieved. The company reiterated its full-year revenue guidance despite outperforming it in the first half. The stock currently trades at a forward P/E ratio typical for mature pharmaceutical firms rather than high-growth biotechs like Aurinia.
Tickers: $AUPH
Topics: biotech pharmaceuticals profitability revenue_growth